"目录号: HY-14558
GPCR/G ProteinNeuronal Signaling-
Tandospirone(SM-3997)是5-HT1A受体部分激动剂，Ki为27 nM，对SR-2，SR-1C，_alpha_1，_alpha_2，D1和D2受体的Ki为1300到41000 nM。
相关产品
Clozapine N-oxide-Chlorpromazine hydrochloride-Pimavanserin-Brexpiprazole-Lorcaserin Hydrochloride-Scopolamine hydrobromide-Cariprazine hydrochloride-Harmine-Lu AE58054 Hydrochloride-TG6-10-1-Perphenazine-Aripiprazole-Ferulic acid sodium-Olanzapine-Sertindole-
生物活性
Description
Tandospirone(SM-3997) is a potent and selective 5-HT1A receptor partial agonist (Ki = 27 nM) that displays selectivity over SR-2, SR-1C, α1, α2, D1 and D2 receptors (Ki values ranging from 1300-41000 nM). IC50 Value: 27±5 nM(Ki) [1]Target: 5-HT1Ain vitro: Tandospirone is most potent at the 5-HT1A receptor, displaying a Ki value of 27 +/- 5 nM. The agent is approximately two to three orders of magnitude less potent at 5-HT2, 5-HT1C, alpha 1-adrenergic, alpha 2-adrenergic, and dopamine D1 and D2 receptors (Ki values ranging from 1300 to 41000 nM). Tandospirone is essentially inactive at 5-HT1B receptors; 5-HT uptake sites; beta-adrenergic, muscarinic cholinergic, and benzodiazepine receptors [1]. 3H-SM-3997 bound rapidly, reversibly and in a saturable manner with high affinity to rat brain hippocampal membranes (Kd = 9.4 nM, Bmax = 213 fmol/mg protein) [2]. in vivo: Chronic treatment with tandospirone, at 0.2 and 1.0mg/kg/day, but not 2.0mg/kg/day, attenuated footshock stress-induced eLAC elevation in the mPFC [3]. Rats were acutely administered tandospirone (0, 0.1, and 1 mg/kg, i.p.). Tandospirone decreased the number of premature responses, an index of impulsive action, in a dose-dependent manner [4].Toxicity: It is not believed to be addictive but it is known to produce mild withdrawal effects (e.g. anorexia) after abrupt discontinuation.
Clinical Trial
Sumitomo Pharmaceutical (Suzhou) Co., Ltd.
Generalized Anxiety Disorder
November 2011
Phase 4
Qingyun Yin-Guangzhou Psychiatric Hospital
Schizophrenia
February 2014
Phase 4
Zhejiang Provincial People’s Hospital
Alzheimer Disease-Cognitive Function
May 20, 2017
Phase 4
View MoreCollapse
References
